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A B S T R A C T
Characterisation of the mode of action (MOA) of constitutive androstane receptor (CAR)-mediated rodent liver
tumours involves measurement 5 key events including activation of the CAR receptor, altered gene expression,
hepatocellular proliferation, clonal expansion and increased hepatocellular adenomas/carcinomas. To test
whether or not liver 3D microtissues (LiMTs) recapitulate CAR- mediated procarcinogenic key events in response
to the prototypical CAR activator phenobarbital (PB) we performed hepatocyte proliferation (LI%) analysis in rat
and human LiMTs using a microTMA technology in conjunction with integrated transcriptomics (microarray)
and proteomics analysis. The rationale for this approach was that LiMTs containing parenchymal and non-
parenchymal cells (NPCs) are more physiologically representative of liver and thus would generate data more
relevant to the in vivo situation. Rat and human LiMTs were treated with PB over a range of concentrations
(500 uM - 2000 uM) and times (24 h - 96 h) in a dose-response/time-course analysis. There was a dose-dependent
induction of LI% in rat LiMTs, however there was little or no eﬀect of PB on LI% in human LiMTs. ATP levels in
the rat and human LiMTs were similar to control in all of the PB treatments. There was also a dose- and time-
dependent PB-mediated RNA induction of CAR regulated genes CYP2B6/Cyp2b2, CYP3A7/Cyp3a9 and
UGT1A6/Ugt1a6 in human and rat LiMTs, respectively. These CAR regulated genes were also upregulated at the
protein level. Ingenuity pathways analysis (IPA) indicated that there was a signiﬁcant (Z score>2.0;-log p
value>) activation of CAR by PB in both human and rat LiMTs. These results indicate that human and rat LiMTs
showed the expected responses at the level of PB-induced hepatocyte proliferation and enzyme induction with
rat LiMTs showing signiﬁcant dose-dependent eﬀects while human LiMTs showed no proliferation response but
did show dose-dependent enzyme induction at the RNA and protein levels. In conclusion LiMTs serve as a model
to provide mechanistic data for 3 of the 5 key events considered necessary to establish a CAR-mediated MOA for
liver tumourigenesis and thus can potentially reduce the use of animals when compiling mechanistic data
packages.
1. Introduction
Liver tumours are a common occurrence in rodent 2 year bioassay
tests of drugs and pesticides. In some cases the process of carcinogenesis
involves activation of nuclear hormone receptors via mechanisms that
are not considered relevant to humans [1]. One such mechanism in-
volves activation of the constitutive androstane receptor (CAR) [2].
Recent methods for testing this mode of action involving modiﬁed
Bradford Hill considerations of causality have established ﬁve key
events in the process of CAR - mediated liver carcinogenesis: 1. Acti-
vation of CAR nuclear receptor; 2. Altered gene expression secondary to
CAR activation; 3. Increased hepatocellular proliferation; 4. Increased
clonal expansion leading to increased altered foci and 5. Increased
hepatocellular adenomas, carcinomas [3,4]. A stepwise scheme for this
purpose involving establishment of key events and associated events in
the process has been outlined in the International Programme on
Chemical Safety (IPSC) framework. The approach also facilitates as-
sessment of human relevance of the mode of action by incorporating a
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comparison of key events in rodent and human in vitro models.
Current in vitro methods for rodent versus human comparisons of
CAR-mediated liver carcinogenesis key events have utilised 2D cultures
of primary hepatocytes [4]. Whilst 2D cultures of primary hepatocytes
have in many cases recapitulated CAR ‘key event’ responses such as
hepatocyte proliferation and enzyme induction [5,6] these cultures
rapidly lose CAR responsiveness after a few days in culture [7,8]. As
certain key event and associated event responses to CAR activation in
vivo by prototypical CAR activators, e.g. phenobarbital (PB), such as
CAR activation and enzyme induction occur over long term (weeks)
exposures [9,10] the use of 2D cultures as models for the in vivo si-
tuation is suboptimal. 3D liver microtissue models containing primary
hepatocytes and non-parenchymal cells, unlike 2D primary hepato-
cytes, retain 'liver like' gene expression proﬁles and also sustain re-
sponsiveness to enzyme inducers such as phenobarbital (PB) for several
weeks in culture [11]. Hence these models oﬀer the potential to provide
an in vitro system that more closely represents in vivo liver responses.
To test this hypothesis we utilised novel high throughput histology,
transcriptomics and proteomics approaches to investigate three ‘key
event’ responses in CAR mediated carcinogenesis, namely CAR activa-
tion, enzyme induction and hepatocyte proliferation in a 3D liver mi-
crotissue model.
2. Materials and methods
2.1. Liver microtissue (LiMT) treatments
InSphero LiMT rat (primary hepatocytes, co-cultured with NPCs
(InSphero #MT-02-00104) and human LiMT (multi-donor primary he-
patocytes, co-cultured with NPCs (InSphero #MT-02-302-04) were
treated with a stock solution of 200mM PB in fresh 3D Insight rat liver
maintenance medium (InSphero #CS-07-002-01) and 3D Insight human
liver maintenance medium-AF (InSPhero #CS-07001a-01), respec-
tively, to give ﬁnal concentrations of 500 uM, 750 uM, 1mM and 2mM;
an HGF (Sigma #H9661-5UG) positive control was included at a con-
centration of 50 ng/ml (rat) and 100 ng/ml (human). The rat and
human LiMTs were exposed, one spheroid per well, in a 96 well gravity
trap™ plate, to PB dissolved in rat or human liver maintenance medium,
respectively, for four diﬀerent time periods: 24 h, 48 h, 72 h and 96 h.
Experiments were performed at least twice on diﬀerent batches of
spheroids. 24 h prior to ﬁxing a media change was performed using
media containing BrDU (10 uM) (Sigma #B5002-100mg), Fig. 1. After
incubation of the spheroids for the appropriate periods of time, LiMTs
were ﬁxed in 4% paraformaldehyde [Pierce 16% paraformaldehyde
(Thermo Fisher Scientiﬁc #28908)], diluted in DPBS (ThermoFisher
#14190-094) for 30min at room temperature after which they were
rinsed in DPBS.
2.2. Spheroid tissue microarray (microTMA) construction
To facilitate high-throughput histology analysis of LiMTs, paraf-
ormaldehyde (4%) ﬁxed spheroids from each drug treatment were
systematically organised in a microTMA using a previously published
method (MicroMatrices international patent application No. PCT/
GB2016/053907 publication number WO 2017/174955; Plummer et al
2019). Brieﬂy, ﬁxed spheroids were loaded into the wells of a 2%
agarose mold containing 96 wells and sealed using molten 0.7%
agarose. We embedded 16 spheroids per treatment in the microTMA
mold. The agarose mold containing spheroids was dehydrated for a
minimum of 12 h in 70% ethanol and then the microTMA mold was
processed to paraﬃn wax in a tissue processor (Thermo Citadel 1000).
Following wax embedding the microTMA block was sectioned (6 uM
sections) using a microtome (Reichert Jung) onto glass microscope
slides.
2.3. Immunostaining
MicroTMA slides were dewaxed in Histoclear and then heat induced
epitope retrieval (HIER) was performed using citrate buﬀer solution
pH6 (Vector labs). Parallel sections were either haematoxylin and eosin
stained or immunostained. Anti-BrDU dual immunoﬂuorescence (IF)
staining was performed as follows: microTMA slides were dewaxed
(Histoclear), rehydrated through graded ethanols (100%-70%) and
subjected to HIER in pH 6.0 citrate buﬀer for 20min at 121 °C in an
antigen retriever (Prestige Medical). After HIER, the slides were washed
in distilled water, and mounted in PBS on a Shandon disposable im-
munostaining chamber according to the manufacturer’s instructions.
Blocking buﬀer (1% BSA (Sigma A7906-100 G), 0.2% Triton X 100
(VWR #3063324), 3% normal goat serum (Sigma G9023-10ml) in PBS)
was added to the chamber and the slides incubated for 2 h at RT. Anti-
BrDU (Abcam #ab152095) primary antibody at a 1:200 dilution (PBS/
0.1% BSA, 0.5% normal goat serum, 0.2% Triton), which included a
primary antibody negative control (wash buﬀer alone), was then added
to the chambers and the slides incubated at RT for 1 h. Slides were
washed in wash buﬀer (0.1% BSA, 0.2% Triton, 0.5% normal goat
serum in PBS). The secondary antibody goat anti-rabbit Alexa ﬂuor 568
(Life Technologies # A11011) diluted at 1:500 in wash buﬀer, was
added to the chamber and the slides incubated for 2 h at RT. The slides
were then washed in wash buﬀer and Sytox green nuclear stain (Life
Technologies #S7020) diluted at 1:1000 in wash buﬀer was added to
the chamber and the slides were incubated for 5min. The slides were
washed in PBS and mounted using antifade mountant (Vectashield,
Vector Laboratories # H-1000). The IF-stained slides were imaged using
a Zeiss 710 LSM confocal microscope.
Fig. 1. Schematic showing the treatment
schedule of rat and human LiMT plates in both
the enabling and main studies.
Green dots show addition of treatment media
without BrDU. Yellow dots show addition of
the treatment media plus BrDU which was
added for last 24 hs of the treatment interval.
Red dots show harvesting the tissues at the end
of the 24, 48, 72 and 96 h intervals.
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2.4. Image analysis
ImageJ (FIJI) software was used for image analysis. Cell counts were
based on detection of nuclear staining by the nuclear ﬂuorescent dye
Sytox green. Each image was thresholded in the Sytox green channel
and quantitation of selected nuclear objects (Sytox green stained) was
performed based on size (excluding objects too small or large for he-
patocyte nuclei) using ﬁlters designed to exclude non-parenchymal
cells. Thresholded and selected nuclei were counted using a script in
Image J (FIJI) software. The BrdU labelling index (LI%) for rat or
human hepatocytes was calculated using the following equation:
LI (%)=100 × (Number of Labelled Nuclei - BrdU+)/(Total number
nuclei in spheroid section– Sytox green)%
2.5. RNA extraction and transplex labelling
2-4 whole ﬁxed spheroids for each treatment were lifted from the 96
well LiMT plates. RNA from these samples was extracted using the
Qiagen miRNeasy FFPE Kit according to the Qiagen RNeasy FFPE
Handbook 09/2011. The RNA yield was quantiﬁed using a Nanodrop
spectrophotometer and extracted RNA was treated with DNase to re-
move any trace of genomic DNA. 50 ng of RNA was used to generate
ampliﬁed cDNA with the Sigma TransPlex Whole Transcriptome
Ampliﬁcation system.The cDNA was puriﬁed then quantiﬁed via
Nanodrop spectroscopy. 1800 ng of cDNA generated in the transplex
reaction was labelled using the Agilent SureTag DNA labelling Kit and
the speciﬁc activity (pmol Cy3/ug cDNA) and concentration (ug/ml) of
labelled cDNA were quantiﬁed by NanoDrop spectroscopy. A speciﬁc
activity of 15–50 pmol Cy3/ug DNA was considered suﬃcient for hy-
bridisation on Agilent arrays.
2.6. Microarray hybridisation and scanning
1800 ng of puriﬁed Cy3-labeled cDNA samples were combined with
Agilent-CGH block and Agilent 2x Hi-RPM Hybridisation Buﬀer (com-
ponents of the Agilent Oligo aCGH/ChiP-on-chip Hybridisation kit).
Hybridisation to Agilent Whole Genome Expression microarrays was
performed at 20 RPM at a temperature of 65 °C for 17 h. Washing steps
were performed according to the Agilent Oligonucleotide Array-Based
CGH for Genomic DNA Analysis Protocol. The Agilent Scanner was
equipped with extended dynamic range (XDR) software and Agilent
Feature Extraction Software was used for the data extraction from raw
microarray image ﬁles to generate raw microarray data. Raw micro-
array data was normalised using R 2.15.2 for Windows with a quantile
algorithm using the following packages:“BiocLite.R”, “limma” version
3.14.0, “Agi4×44PreProcess” version 1.22.0. All packages used de-
fault analysis parameters.
2.7. CAR signature pathways analysis of diﬀerentially expressed gene
(DEG) lists
Following statistical analysis, Ingenuity Pathways Analysis (IPA)
was used to identify pathways regulated by the induction of CAR
(constitutive androstane receptor). A focussed IPA overrepresentation
analysis against a CAR signature gene list derived by Oshida and co-
workers (Oshida et al., 2015) was performed. The Oshida CAR sig-
nature gene list was imported into IPA and a Tox Analysis was per-
formed against both rat and human DEG data in order to test the eﬀect
of treatments on the overrepresentation (Fisher’s Exact Test -log p va-
lues) of this pathway in the DEG lists. As IPA overrepresentation
(Fisher's exact test) analysis does not take into account the polarity of
gene expression changes in the CAR regulated genes in the DEG lists,
the polarity of gene expression changes was assessed by reviewing ex-
ported Excel data tables for the CAR signature pathway to determine
whether or not CAR-regulated genes were induced. The -Log p values in
IPA also do not distinguish activation or repression of a pathway. We
utilised Z score values in an upstream regulator analysis to assess the
signiﬁcance of activation or repression of the CAR receptor (NR1I3).
2.8. Proteomic analysis
Control and PB treated rat LiMTs and human LiMTs (23 spheroids/
sample) were extracted and placed into 8 Protein Lo-bind tubes. Rat
and Human LiMTs were analysed at the 72 h and 96 h time points, re-
spectively, based on an assessment of the kinetics of PB induction of
certain CAR regulated ‘signature’ genes at the RNA level where it was
found that there was maximal induction of Cyp2B2 and CYP2B6 at 72 h
and 96 h for rat and human LIMTs, respectively (see Results section-
enzyme induction). In rat LiMTs, 8 samples (30 spheroids/sample) were
generated, of which 4 were controls and 4 were PB treated, and the
analysis was performed for control and PB 750 uM treated samples at
the 72 h time point.
Protein was extracted from ﬁxed samples using the Qproteome FFPE
Tissue kit (QIAGEN) according to the manufacturer's instructions and
protein concentration was measured using the EZQ method (EZQ®
Protein Quantitation Kit, Invitrogen). Protein was then precipitated by
adding methanol and chloroform, followed by overnight Trypsin di-
gestion. Peptides were TMT labelled (TMT 10plex Reagent Kit, Thermo
Scientiﬁc) and the labelled samples were combined and puriﬁed. 4
fractions were produced from the combined sample via oﬄine HPLC on
an XBridge BEH C18 Column. These fractions were evaporated to
dryness and resuspended in 1% formic acid prior to injection into the
Lumos Fusion Orbitrap LC MS/MS followed by analysis to raw data.
2.9. Statistical analysis of transcriptomics and proteomics data
Fold change values in the transcriptomics analysis were calculated
in R software using a linear model for microarray data analysis
(LIMMA), and Benjamini Hochberg multiple test correction was applied
to p values derived from the t-test analysis to derive q values [false
discovery rate (FDR) adjusted p values] for these alterations.This pro-
cess was used to identify a list of diﬀerentially expressed genes (DEG
list), relative to control, for each of the treatments using a cut oﬀ point
for the q value derived from the LIMMA t-test set at p < 0.05.
Proteomics data was analysed in Proteome Discoverer 2.1 and microsoft
Excel softwares. Raw intensity values for each peptide were normalised
by taking the channel (isobaric tag) in the 8 plex analysis with the
highest total peptide abundance value and then correcting all the other
channels by a constant factor so that all channels had the same total
abundance value. These normalised values were then scaled for every
peptide so that the average of all channels had an intensity of 100 in-
tensity units. A fold change and p value was calculated from 4 replicate
data points for each treatment using Student t-test in Excel.
2.10. Integration of rat and human proteomic and transcriptomic data
Processed data from the transcriptomic experiments was uploaded
to IPA simultaneously with the proteomic data produced from
Proteome Discoverer analysis. Integration of the transcriptomic and
proteomic data was performed subsequent to normalisation and sta-
tistical analysis using an R script that combined the data using the
Genbank/Uniprot abbreviated gene names. Rat and human integrated
datasets were uploaded to IPA for bioinformatics analysis.
3. Results
3.1. Hepatocyte proliferation
There was a dose- and time-dependent induction of hepatocyte
proliferation (LI%) in rat LiMTs at the 48 h, 72 h and 96 h time points
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Fig. 2. Eﬀect of PB treatments on hepatocyte proliferation (LI%) in rat and human LiMTs.
(A) rat and (B) human LiMTs showing representative images of H&E stained (top panels) or anti-BrDU immunoﬂuorescence (IF) stained (bottom panels) LiMTs from
parallel microTMA sections. (C) and (D) are histograms of hepatocyte proliferation (LI%) data derived from image analysis of BrDU IF stained rat and human LiMT
sections, respectively. Results are mean ± SD, n=4-8. *, **, *** signiﬁcantly diﬀerent from control by Student's t test, p < 0.05, p < 0.001, p < 0.0001,
respectively. The data ware representative of at least two separate experiments performed on diﬀerent batches of spheroids.
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which peaked at the 96 h time point, Fig. 2C. At the 24 h time point
there was a high basal level of proliferation in the control rat LiMT
samples which may be attributed to a stress response caused by as-
sembly/shipment of the spheroids. By contrast there was no signiﬁcant
induction of LI% by PB at any of the doses or time points in human
LiMTs, Fig. 2D. Hepatocyte growth factor (HGF) treatments caused a
signiﬁcant induction of LI% in both rat and human LiMTs, Fig. 2C and
D, respectively. The levels of ATP in rat and human LiMTs following PB
treatments were not signiﬁcantly diﬀerent from control indicating that
the PB treatment did not cause cytotoxicity, Table 1. Histopathological
examination of H&E sections of the spheroids following the treatments
also showed no signs of central necrosis, Fig. 2A and B. There was some
vacuolation in the hepatocytes of both rat and human LiMTs but the
ﬁnding is not considered signiﬁcant in view of the functional response
to PB evidenced by the induction by PB of CAR regulated genes at the
RNA and protein level (see below).
3.2. Enzyme induction
There was a dose- and time-dependent PB-mediated induction of
CAR regulated genes CYP2B6, CYP3A7, UGT1A6 and UGT1A8 (Oshida
et al 2015, Gardner-Stephen et al 2003, Shelby and Klassen 2006) in
human LiMTs and of Cyp2b2, Cyp3a9, Ugt1a6 in rat LiMTs, Fig. 3A–F
and Supplementary data Tables 1 and 2, respectively. There was an
apparent diﬀerence between rat and human LiMTs in the kinetics of
onset of CYP3A7 induction which was induced at an earlier time point
in rat LIMTs compared to human LiMTs, Fig. 3B and E, respectively.
Ugt1a8 RNA was not upregulated by PB in rat LiMTs indicating a
species diﬀerence with human LiMTs at this level (data not shown).
Human isoforms CYP2B6, CYP3A7 and UGT1A6 and rat isoforms
Cyp2b2, Cyp3a7 were also induced at the protein level, Supplementary
data Tables 1 and 2 respectively. Ugt1a6 was not detected in the pro-
teomics analysis of the rat LiMTs which likely reﬂects a lower abun-
dance of this isoform at the protein level in rat LiMTs compared to
human LiMTs, Supplementary data Table 2.
3.3. Pathways analysis
Integrated transcriptomics and proteomics analysis showed that PB
treatment caused diﬀerential expression of genes at both the RNA and
protein level and the number of diﬀerentially expressed genes was for
the most part dose-dependant. PCA analysis of the data indicated that
both the human and rat data broadly segregates according to treatment,
Fig. 1, supplementary data. IPA pathways analysis showed there was a
signiﬁcant (p < 0.05) over-representation of CAR/PXR activation
pathways genes in the human and rat LiMT RNA DEG lists at several PB
doses at the 24 h, 48 h, 72 h and 96 h time points, Fig. 4A and B, re-
spectively. The CAR/PXR activation pathway genes were mostly
Table 1
ATP levels in the rat and human LiMTs after PB (500 uM, 750 uM, 1000 uM
and 2000 uM) treatments. Results are means ± SD, n= 2-4. N/D=not de-
termined.
Treatment Rat LiMTs Human LiMTs
ATP pmoles/LMT ATP pmoles/LMT
control 11.8 ± 1.1 15.2 ± 5.1
PB 500 uM 17.4 ± 0.3 N/D
PB 750 uM 18.6 ± 2.0 15.0 ± 4.8
PB1000 uM 19.2 ± 2.0 13.8 ± 4.8
PB 2000 uM 20.1 ± 2.4 16.0 ± 2.8
Fig. 3. Eﬀects of PB treatment over time on the induction (fold change) of CAR-regulated genes.
(A) rat Cyp2B2; (B) rat Cyp3A7; (C) rat Ugt1A6; (D) human CYP2B6; (E) human CYP3A7; (F) human CYP1A6. NB: Red/orange/Green data bars show fold change
values signiﬁcantly (Adjusted p < 0.05) diﬀerent from control. Blue data bars show non-signiﬁcant (Adjusted P > 0.05) fold change data values. PB1 = pheno-
barbital 500 uM; PB2 = phenobarbital 750 uM; PB3 = phenobarbital 1000 uM; PB4 = phenobarbital 2000 uM.
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induced (2–15 fold) at the RNA level by PB treatment, Supplementary
data Tables 1 and 2. Several of the CAR/PXR activation pathway genes
were also signiﬁcantly (P < 0.05) induced at the protein level in both
human and rat LiMTs, Supplementary data Tables 1 and 2, respectively.
IPA Z score analysis of the RNA DEGs indicated that there was a sig-
niﬁcant (Z score> 2.0) activation of CAR by PB treatments at the 48,
72 and 96 h time points in human LiMTs and at the 48 h and 72 h time
points in rat LiMTs, Table 3A and B, respectively. IPA analysis of pro-
tein level DEGs also indicated that CAR and PXR were activated, Sup-
plementary data Table 3.
4. Discussion
Human and rat LiMTs gave the expected responses at the level of
PB-induced hepatocyte proliferation (LI%) in that rat LiMTs showed a
signiﬁcant dose-dependent increase in Li% whereas human LiMTs did
not. The data showed fairly high variability reﬂected in the standard
deviation values hence for regulatory studies with new agents it may be
necessary to double the number of biological replicates to 8 for this
analysis. This data is consistent with previous studies with 2D cultures
of primary human and rat hepatocytes [5,6] and indicates that the 3D
LiMT model is suitable for assessing human/rat species diﬀerences at
this level. Our data show that the proliferative response to PB in rat
LiMTs is maintained for up to 96 h indicating that rat primary hepa-
tocytes in this 3D model maintain their responsiveness to PB for a
longer period than 2D cultures [12]. Previous studies in this LiMT
model and also in 2D rat hepatocytes cultured with dexamethazone
have shown that the PB induced enzyme induction is maintained for up
to 28 days ([11,13], indicating the signalling mechanisms necessary to
support enzyme induction responses remains functional when the he-
patocytes are grown in 2D or 3D. Our data shows that certain Cyp RNA
induction responses of rat LiMTs (e.g Cyp2b2, Cyp3a7) unlike those of
human LiMTs (CyP2B6, CYP3A7) appeared to decline at later time
points (72 h, 96 h). However there was no indication of a decline in the
induction of these isoforms at the protein level as they were both sig-
niﬁcantly induced at the later time point(s). The reason for the reduced
Fig. 4. Comparison of over-representation of Ingenuity CAR/RXR ativation pathway genes in the DEG lists derived from a transcriptomic analysis of PB treated
human and rat LiMTs.
(A) human LiMTs treated with PB; (B) rat LiMTs treated with PB. Histogram columns show false discovery rate (FDR) adjusted p values (-Log p value) for treatments
according to PB dose and time. A p value of< 0.05 (-log p value>1.3) was considered signiﬁcant. The orange horizontal line shows this -log p value 1.3 threshold.
N/S=not signiﬁcant.
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level of induction of certain rat Cyp RNAs at the longer time points by
PB is unclear, however our ATP assay data showing similar or slightly
increased levels of ATP in PB treated compared to control rat LiMTs
suggests that this cannot be attributed to cytotoxicity. The apparent
dose-dependent increase in levels of ATP in the rat LIMTs may reﬂect
increased proliferation rates in these tissues. The rat LiMT RNA in-
duction response for Ugt1a6 was maintained across the whole time
course.
There was also a species diﬀerence in the induction of (UGT1A8) as
this UGT isoform was induced by PB in human LiMTs but not in rat
LiMTs. Lack of induction of Ugt1a8 by PB in rat LiMTs is consistent with
previous in vivo liver RNA induction data for PB with this isoform in
rats [14].
There was a signiﬁcant over-representation of genes in the CAR/
RXR activation pathway at all time points in the transcriptomics DEG
lists in both rat and human LiMTs and the predicted activation of this
CAR pathway was dose- and time-dependant in human LiMTs but not in
rat LiMTs (Table 2).
The results of the present study indicate the the 3D LiMT model is ﬁt
for the purpose of assessing several key events necessary for estab-
lishing a CAR-mediated MOA for rat liver tumours and for assessing the
human relevance of this response. Being able to perform these tests in
an in vitro model will facilitate a reduction in the use of animals for this
purpose.
Integrating the analysis of hepatocyte proliferation and enzyme
induction in a single in vitro assay increases the eﬃciency of a me-
chanistic investigation, and because the analysis of LIMTs using the
microTMA platform uses existing robotic staining and laser dissection
technology it is possible to perform tests at an earlier stage in pre-
clinical testing, making this approach suitable for compound screening/
lead selection. This could potentially reduce the incidence and costs of
adverse liver tumour events attributable to a CAR mode of action in
later 2 year bioassay tests. Broadening the pathways analysis process to
encompass ‘signatures’ for other nuclear hormone receptors such as
peroxisome proliferator activated receptor alpha (PPARA) [15] and aryl
hydrocarbon receptor (AHR) [16] would also oﬀer the opportunity to
avoid non-human relevant adverse outcomes with other classes of non-
genotoxic liver carcinogens. Furthermore since the induction of tu-
mours in other tissues have also been mechanistically linked to acti-
vation of nuclear hormone receptors in the liver [17–19], this approach
could also reduce the occurrence and associated costs in terms of
compound attrition caused by these adverse events.
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.toxrep.2019.09.010.
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